Neumous develops therapeutic ultrasound medical devices that utilize focused ultrasound to non-invasively open the blood-brain barrier, enabling targeted delivery of therapeutic agents for treating brain diseases such as tumors and Alzheimer's. This technology allows for real-time monitoring and personalized adjustments to optimize treatment efficacy without the need for surgical intervention.
Funding
Funding not disclosed
Founders
Product
Problem
Treating brain diseases like tumors and Alzheimer's is challenging due to the blood-brain barrier (BBB), which restricts the delivery of therapeutic agents to the brain. Traditional methods for bypassing the BBB often involve invasive surgical procedures. Many drugs that could potentially treat brain diseases are ineffective because they cannot cross the BBB.
Solution
Neumous is developing therapeutic ultrasound medical devices that non-invasively open the blood-brain barrier (BBB), enabling targeted drug delivery to treat brain diseases. The focused ultrasound technology allows clinicians to temporarily and safely open the BBB in a specific brain region. Real-time monitoring capabilities allow for personalized adjustments to optimize treatment efficacy. This approach enables the delivery of drugs and therapeutic agents to the brain without conventional surgery, potentially repurposing drugs that previously failed due to BBB impermeability.
Target Audience
The primary target audience includes medical professionals and researchers focused on treating brain diseases such as brain tumors and Alzheimer's, as well as pharmaceutical companies seeking to improve drug delivery to the brain.
Features
- Non-invasive BBB opening using focused ultrasound technology
- Real-time monitoring of BBB opening extent and location
- Personalized treatment adjustments based on real-time monitoring data
- Compatibility with various therapeutic agents for targeted drug delivery
- Potential for drug repositioning of ineffective drugs due to BBB impermeability